Kymera CEO exercises options, sells 50K shares

Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported an option exercise and related stock sale.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported an option exercise and related stock sale. He exercised stock options to acquire 50,000 shares of Common Stock at an exercise price of $2.08 per share, then sold 50,000 Common shares at an average price of $119.00 per share.

Following these transactions, he directly owned 666,568 Common shares. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and the options involved were fully vested and exercisable.

Insider Trade Summary 10b5-1

Exercise and Sale: 50,000 shares ($5.85M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Mainolfi Nello

Role Chief Executive Officer

Sold 50,000 shs ($5.95M)

Approx. gross sale proceeds $5.95M

Approx. exercise cost $104K

Approx. pre-tax spread $5.85M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	45,559	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	4,441	$0.00	$0.00
Exercise	Common Stock	50,000	$2.08	$104K
Sale	Common Stock	50,000	$119.00	$5.95M

Holdings After Transaction: Stock Option (Right to Buy) — 104,284 contracts (Direct); Common Stock — 666,568 shares (Direct)

Footnotes (2)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
2. F2. The shares underlying this stock option are fully vested and exercisable.

Key Figures

Shares sold: 50,000 shares Sale price: $119.00 per share Options exercised: 50,000 shares +4 more

7 metrics

Shares sold 50,000 shares Common Stock open-market sale on 2026-07-07 at $119.00

Sale price $119.00 per share Price for 50,000 Common shares sold on 2026-07-07

Options exercised 50,000 shares Shares acquired via option exercise on 2026-07-07

Option exercise price $2.08 per share Conversion or exercise price for stock options exercised

Post-transaction holdings 666,568 shares Common Stock directly owned after transactions

Rule 10b5-1 plan date March 24, 2026 Trading plan governing these transactions

Option expiration date November 13, 2029 Expiration for stock options at $2.08 exercise price

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), open-market sale, Exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" with underlying security title Common Stock."

open-market sale financial

"transaction_action: "open-market sale" for 50,000 shares of Common Stock at $119.0000 per share."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security" for the option transactions."

fully vested and exercisable financial

"The shares underlying this stock option are fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kymera (KYMR) CEO Nello Mainolfi do in this Form 4 filing?

Nello Mainolfi exercised stock options for 50,000 Kymera shares at $2.08 per share and sold 50,000 Common shares at $119.00 per share. These transactions are reported as part of his direct ownership in the company.

How many Kymera (KYMR) shares does the CEO hold after these transactions?

After the reported transactions, CEO Nello Mainolfi directly holds 666,568 shares of Kymera Common Stock. This figure comes from the Form 4 and reflects his direct ownership position following the option exercise and subsequent share sale.

At what prices did the Kymera (KYMR) CEO exercise and sell shares?

Nello Mainolfi exercised stock options at an exercise price of $2.08 per Kymera share and sold 50,000 Common shares at an average price of $119.00 per share. These prices are explicitly disclosed in the Form 4 filing.

Were the Kymera (KYMR) CEO’s trades made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026. Such plans are pre-arranged trading programs that schedule transactions in advance under predetermined conditions.

What type of securities were involved in the Kymera (KYMR) CEO’s Form 4?

The filing covers Kymera Common Stock and related stock options described as “Stock Option (Right to Buy).” The options were fully vested and exercisable, and their exercise led to the acquisition of 50,000 Common shares reported in the non-derivative transactions table.

What do the stock options in the Kymera (KYMR) Form 4 represent?

The stock options, labeled “Stock Option (Right to Buy),” give the CEO the right to purchase Kymera Common Stock at a conversion price of $2.08 per share until their stated expiration date. The filing notes the underlying option shares are fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		M(1)		50,000	A	$2.08	716,568	D
Common Stock	07/07/2026		S(1)		50,000	D	$119	666,568	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.08	07/07/2026		M(1)			45,559	(2)	11/13/2029	Common Stock	45,559	$0	90,000	D
Stock Option (Right to Buy)	$2.08	07/07/2026		M(1)			4,441	(2)	11/13/2029	Common Stock	4,441	$0	14,284	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.

2. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)